Human ubiquitin-activating enzyme, E1. Indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs - PubMed
- ️Sat Jan 01 1994
. 1994 Dec 30;269(52):33171-8.
Affiliations
- PMID: 7528747
Free article
Human ubiquitin-activating enzyme, E1. Indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs
P M Handley-Gearhart et al. J Biol Chem. 1994.
Free article
Abstract
The ubiquitin-activating enzyme E1 catalyzes the first step in the ubiquitin conjugation pathway. Previously, we have cloned and sequenced the cDNA for human E1. Expression of the E1 cDNA in the ts20 cell line, which harbors a thermolabile E1, abrogated the phenotypic defects associated with this line. However, little is known of the cell biology of the E1 protein or the nature of the E1 doublet. Thus, we constructed epitope-tagged E1 cDNAs in which the HA monoclonal antibody epitope tag sequence (from influenza hemagglutinin and recognized by the 12CA5 monoclonal antibody) was fused to the amino terminus of E1. Because the amino-terminal amino acid sequence of E1 is unknown, three constructs were made in which the HA tag was placed at each of the first three ATGs in the open reading frame (HA-1E1, HA-2E1, and HA-3E1). Western analysis of HeLa cells transfected with the constructs revealed that HA-1E1 closely comigrated with the upper band of the E1 doublet, and HA-2E1 comigrated with the lower band of the E1 doublet; HA-3E1 appeared smaller than either of the E1 bands. Metabolic labeling with 32P and immunoprecipitation with anti-HA antibody revealed that only the HA-1E1 protein product is phosphorylated; polyclonal anti-E1 antibody showed that only the upper band of the endogenous E1 doublet is phosphorylated. Each of the constructs was able to rescue the mutant phenotype of the ts20 cell line. Immunofluorescence studies showed that HA-2E1 and HA-3E1 were distributed in the cytoplasm with both negative and positive nuclei. This pattern of distribution has also been observed when immunostaining with a monoclonal antibody to E1 (1C5). However, the staining pattern associated with a polyclonal anti-E1 antibody (JJJ) is characterized by positive staining cytoplasm and nuclei in all cells. The HA-1E1 construct exhibited apparently exclusive nuclear distribution in HeLa cells. The difference between the staining patterns of the polyclonal and monoclonal anti-E1 antibodies can be explained by the existence of two subpopulations of E1: one cytoplasmic and partially nuclear, and one that is nuclear. Deletion of a small region at the amino terminus of the HA-1E1, including the basic sequence KKRR, transformed its immunostaining pattern to that observed with HA-2E1.
Similar articles
-
Stephen AG, Trausch-Azar JS, Handley-Gearhart PM, Ciechanover A, Schwartz AL. Stephen AG, et al. J Biol Chem. 1997 Apr 18;272(16):10895-903. doi: 10.1074/jbc.272.16.10895. J Biol Chem. 1997. PMID: 9099746
-
Trausch JS, Grenfell SJ, Handley-Gearhart PM, Ciechanover A, Schwartz AL. Trausch JS, et al. Am J Physiol. 1993 Jan;264(1 Pt 1):C93-102. doi: 10.1152/ajpcell.1993.264.1.C93. Am J Physiol. 1993. PMID: 8430776
-
Nuclear localization of the ubiquitin-activating enzyme, E1, is cell-cycle-dependent.
Grenfell SJ, Trausch-Azar JS, Handley-Gearhart PM, Ciechanover A, Schwartz AL. Grenfell SJ, et al. Biochem J. 1994 Jun 15;300 ( Pt 3)(Pt 3):701-8. doi: 10.1042/bj3000701. Biochem J. 1994. PMID: 8010951 Free PMC article.
-
Immunoelectron microscopic localization of the ubiquitin-activating enzyme E1 in HepG2 cells.
Schwartz AL, Trausch JS, Ciechanover A, Slot JW, Geuze H. Schwartz AL, et al. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5542-6. doi: 10.1073/pnas.89.12.5542. Proc Natl Acad Sci U S A. 1992. PMID: 1376922 Free PMC article.
-
Nuclear multicatalytic proteinase subunit RRC3 is important for growth regulation in hepatocytes.
Benedict CM, Clawson GA. Benedict CM, et al. Biochemistry. 1996 Sep 10;35(36):11612-21. doi: 10.1021/bi960889p. Biochemistry. 1996. PMID: 8794741
Cited by
-
McHugh A, Fernandes K, South AP, Mellerio JE, Salas-Alanís JC, Proby CM, Leigh IM, Saville MK. McHugh A, et al. Oncotarget. 2018 Apr 17;9(29):20265-20281. doi: 10.18632/oncotarget.24750. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755650 Free PMC article.
-
Shared and distinct mechanisms of UBA1 inactivation across different diseases.
Collins JC, Magaziner SJ, English M, Hassan B, Chen X, Balanda N, Anderson M, Lam A, Fernandez-Pol S, Kwong B, Greenberg PL, Terrier B, Likhite ME, Kosmider O, Wang Y, Samara NL, Walters KJ, Beck DB, Werner A. Collins JC, et al. EMBO J. 2024 May;43(10):1919-1946. doi: 10.1038/s44318-024-00046-z. Epub 2024 Feb 15. EMBO J. 2024. PMID: 38360993 Free PMC article.
-
Sugaya K, Ishihara Y, Inoue S, Tsuji H. Sugaya K, et al. PLoS One. 2014 May 7;9(5):e96666. doi: 10.1371/journal.pone.0096666. eCollection 2014. PLoS One. 2014. PMID: 24805847 Free PMC article.
-
Piedade WP, Famulski JK. Piedade WP, et al. Biochem Soc Trans. 2021 Feb 26;49(1):327-340. doi: 10.1042/BST20200613. Biochem Soc Trans. 2021. PMID: 33616626 Free PMC article. Review.
-
Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond.
Sikora KA, Wells KV, Bolek EC, Jones AI, Grayson PC. Sikora KA, et al. Rheumatology (Oxford). 2022 Aug 3;61(8):3149-3160. doi: 10.1093/rheumatology/keab868. Rheumatology (Oxford). 2022. PMID: 34888629 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials